Swedish Orphan Biovitrum AB (publ)
STO:SOBI

Watchlist Manager
Swedish Orphan Biovitrum AB (publ) Logo
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Watchlist
Price: 290 SEK -0.21% Market Closed
Market Cap: 99.8B SEK
Have any thoughts about
Swedish Orphan Biovitrum AB (publ)?
Write Note

Swedish Orphan Biovitrum AB (publ)
Current Portion of Long-Term Debt

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Swedish Orphan Biovitrum AB (publ)
Current Portion of Long-Term Debt Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Current Portion of Long-Term Debt CAGR 3Y CAGR 5Y CAGR 10Y
Swedish Orphan Biovitrum AB (publ)
STO:SOBI
Current Portion of Long-Term Debt
kr6.1B
CAGR 3-Years
42%
CAGR 5-Years
133%
CAGR 10-Years
123%
Biogaia AB
STO:BIOG B
Current Portion of Long-Term Debt
kr8.8m
CAGR 3-Years
2%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bonesupport Holding AB
STO:BONEX
Current Portion of Long-Term Debt
kr6.4m
CAGR 3-Years
4%
CAGR 5-Years
3%
CAGR 10-Years
N/A
Vitrolife AB
STO:VITR
Current Portion of Long-Term Debt
kr152m
CAGR 3-Years
113%
CAGR 5-Years
61%
CAGR 10-Years
25%
Probi AB
STO:PROB
Current Portion of Long-Term Debt
kr20.7m
CAGR 3-Years
9%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
BioArctic AB
STO:BIOA B
Current Portion of Long-Term Debt
kr2.8m
CAGR 3-Years
-27%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Swedish Orphan Biovitrum AB (publ)
Glance View

Market Cap
99.6B SEK
Industry
Biotechnology

Swedish Orphan Biovitrum AB (publ), often referred to as Sobi, is a biopharmaceutical company that has carved a niche in the development and commercialization of innovative treatments for rare diseases, primarily focusing on hematology, immunology, and specialty care. Founded in 2001 and headquartered in Stockholm, Sobi has garnered a reputation for its commitment to improving the lives of patients with complex medical conditions. The company's portfolio includes several key products that address unmet medical needs, particularly in areas such as hemophilia and other inherited disorders. Through strategic partnerships and acquisitions, Sobi has expanded its capabilities, bolstering its research and development pipeline while strengthening its market presence across Europe, North America, and beyond. As an investor, Sobi presents a compelling opportunity in the growing field of rare diseases, bolstered by a robust regulatory framework that often allows for expedited approval processes for groundbreaking therapies. The company’s focus on precision medicine and its dedication to patient-centric care position it well in an industry characterized by high demand and limited competition. With a solid financial foundation and a proactive approach to innovation, Sobi is poised to capture significant market share in a rapidly evolving landscape. Furthermore, with its strategic initiatives in expanding global reach and investing in next-generation therapies, Sobi exemplifies the principles of value investing by aligning long-term growth potential with the increasing need for specialized medical treatments.

SOBI Intrinsic Value
368.27 SEK
Undervaluation 21%
Intrinsic Value
Price

See Also

What is Swedish Orphan Biovitrum AB (publ)'s Current Portion of Long-Term Debt?
Current Portion of Long-Term Debt
6.1B SEK

Based on the financial report for Sep 30, 2024, Swedish Orphan Biovitrum AB (publ)'s Current Portion of Long-Term Debt amounts to 6.1B SEK.

What is Swedish Orphan Biovitrum AB (publ)'s Current Portion of Long-Term Debt growth rate?
Current Portion of Long-Term Debt CAGR 10Y
123%

Over the last year, the Current Portion of Long-Term Debt growth was 81%. The average annual Current Portion of Long-Term Debt growth rates for Swedish Orphan Biovitrum AB (publ) have been 42% over the past three years , 133% over the past five years , and 123% over the past ten years .

Back to Top